Skip to main content
Arrowhead Pharmaceuticals, Inc.SEC 10-K

Arrowhead raises $216.6 million net proceeds via common stock and pre-funded warrants offering

What happened

5 signals in this filing. On January 7, 2026, the Company entered into an underwriting agreement with Jefferies and J.P. Morgan for an offering of common stock and pre-funded warrants that closed January 9, 2026, raising $230.0 million in...

Source

Extracted by Autobound

From the Signal API record
Signal
SEC 10-K

What this signalsFilings often name leadership changes, deals and spending plans.

Filed
Nov 12, 2026

More SEC 10-K signals at other companies

The full record

From the Signal API record

Numbers

Dollar figuregross proceeds from offering of common stock and pre-funded warrants
$230M

Details

CIK
879407
Accession number
0000879407-26-000078
Timeframe
Current year
Filing year
2026
Fiscal year end
09/30
Why it matters
New capital available
Signal category
Financial

Topics and mentions

Vendors named

  • Jefferies
  • J.P. Morgan

Extraction

Confidence
High
Relevance
85%
Sentiment
Positive
Detected
Nov 17, 2026
signal_type
sec-10k
signal_subtype
equityRaise

Use this data

Get every SEC 10-K signal for Arrowhead Pharmaceuticals, Inc. and the companies you sell to, in the tools you already use.

  1. Ask Claude about it

    Connect Autobound to Claude, Claude Code or Cursor with MCP. Then ask: “What changed at Arrowhead Pharmaceuticals, Inc. this week?”

  2. Send it to your own tools

    The Signal API returns SEC 10-K signals for any list of companies as JSON, for your CRM, warehouse or app.

  3. Try it free

    Sign up and spend your free credits on the companies you sell to.

    Start Free1,000 free credits

The API returns more than this page shows

This page shows a preview. The full sec-10k record in the Signal API and MCP can also have these 8 fields. Some fields are empty for some signals.

Company

  • linkedin_urlValue in the API
  • industriesValue in the API
  • employee_count_lowValue in the API
  • employee_count_highValue in the API
  • revenueValue in the API
  • descriptionValue in the API

Signal

  • signal_nameValue in the API
  • associationValue in the API
Show the full JSONThe record on this page and the API request

GET /v1/signals/fad50495-5238-414b-bf38-91f1fb2cba59 returns this record as JSON. POST /v1/companies/enrich returns every signal for arrowheadpharma.com.

{
  "signal_id": "fad50495-5238-414b-bf38-91f1fb2cba59",
  "signal_type": "sec-10k",
  "signal_subtype": "equityRaise",
  "detected_at": "2026-11-17T07:03:12.715+00:00",
  "company": {
    "name": "Arrowhead Pharmaceuticals, Inc.",
    "domain": "arrowheadpharma.com"
  },
  "data": {
    "detail": "On January 7, 2026, the Company entered into an underwriting agreement with Jefferies and J.P. Morgan for an offering of common stock and pre-funded warrants that closed January 9, 2026, raising $230.0 million in gross proceeds and $216.6 million net proceeds. For sellers: Expanded capital reserves may facilitate further investments in clinical and commercial development.",
    "metrics": {
      "timeframe": "current_year",
      "dollar_context": "gross proceeds from offering of common stock and pre-funded warrants",
      "dollar_millions": 230
    },
    "summary": "Arrowhead raises $216.6 million net proceeds via common stock and pre-funded warrants offering",
    "relevance": 0.85,
    "sentiment": "positive",
    "confidence": "high",
    "source_url": "https://www.sec.gov/Archives/edgar/data/879407/000087940726000078/arwr-20260930.htm",
    "filing_date": "2026-11-12",
    "filing_year": 2026,
    "fiscal_year_end": "09/30",
    "sales_relevance": "New capital available",
    "signal_category": "financial",
    "vendors_mentioned": [
      "Jefferies",
      "J.P. Morgan"
    ]
  }
}

Long text fields are shortened on this page.

Looking up one signal by its id is free. Enrich costs 2 credits per signal returned; a call with no results is free.